Celaid Therapeutics Raises JPY 400 million in Series B Financing to Advance Ex Vivo Hematopoietic Stem Cell (HSC) Expansion
For decades, hematopoietic stem cell transplantation (HSCT) has been one of the most successful cell therapies in medicine, with more than 40,000 transplants performed worldwide each year. Yet the field has a stubborn problem: not every patient who needs a transplant can get one. Ex vivo hematopoietic stem cell (HSC) expansion was designed to solve it, but progress has been slow. Only a handful of companies have pursued the approach, including Gamida Cell in Israel, ExCellThera in Canada, and Plasticell in the United Kingdom. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2027
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
The Exosome Revolution is Here: 1 in 7 Publications Emerged in the Past Year
Exosomes have recently exploded in popularity, with companies developing exosome-based diagnostics, therapeutics, and cosmeceuticals. Although they were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. [Read more…]
What is the difference between totipotent, pluripotent, and multipotent?
When learning about stem cells, a common question is, what is the difference between totipotent, pluripotent, and multipotent cells? The answer is simple.
The key differences between these cells are:
- When each appears during the process of human development.
- Their degree of “flexibility” to become other cell types. [Read more…]
- 1
- 2
- 3
- …
- 202
- Next Page »




